KCM
ALBO

Kennedy Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

Kennedy Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,299
Closed -$386K – 740
2019
Q3 		$386K Sell
19,299
-1,409
-7% -$36.5K 0.01% 649
2019
Q2 		$668K Buy
20,708
+534
+3% +$17.9K 0.02% 634
2019
Q1 		$650K Buy
+20,174
New +$543K 0.02% 644

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kennedy Capital Management's ALBO Position: Q4 2019 in Review

Kennedy Capital Management sold out of Albireo Pharma Inc (ALBO) in Q4 2019, closing a stake of 19,299 shares — an estimated $386K sold.

Kennedy Capital Management first reported a position in ALBO in Q1 2019 and held it in 3 quarters. The position peaked at $668K in Q2 2019. 70 funds tracked by Wall St. Rank hold ALBO as of Q4 2019.

  • Kennedy Capital Management reported no remaining Albireo Pharma Inc position as of Q4 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 19,299 Albireo Pharma Inc shares in Q4 2019, an estimated $386K.
  • Kennedy Capital Management first reported a position in Albireo Pharma Inc in Q1 2019 and held it in 3 quarters.
  • Kennedy Capital Management's Albireo Pharma Inc position peaked at $668K in Q2 2019.
  • 70 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2019.

Based on Kennedy Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.